LLBO Lifeline Biotech Inc (CE)

Lifeline Biotechnologies, Inc. (Pink Sheets: LLBO), a developer of innovative medical technology, today announced that it has reorganized its common stock by a reverse split of one share for each one hundred and fifty (1/150) of issued and outstanding shares as of September 5, 2008. Subsequent to the reverse, there will be approximately 62 million shares of common shares outstanding. In addition the authorized common stock has been reduced to 950 million shares. Jim Holmes, Lifeline�s CEO stated, �The public market for the Company�s publicly traded shares have become illiquid and the reduction of the total outstanding common shares is necessary. The Company has depended on the liquidity of the market as a source of funds to support the development work undertaken on the First Warning System�.� The new trading symbol is LLBO effective at the opening of trading September 5, 2008. Holmes noted that the development work on the First Warning System� continues and updated information on the progress will be available near term. About Lifeline Biotechnologies, Inc: Lifeline Biotechnologies, Inc. is an innovative medical technology company that is focused on completing the development of the First Warning System�, which is designed to assist in the early detection of breast cancer. Of the approximately $138 billion spent on cancer each year, Lifeline�s First Warning System� could potentially save the healthcare industry an estimated $3 to $4 billion annually, assuming the following are successfully completed: development of the First Warning Systems� interpretive, proprietary software, clinical trials and FDA pre-marketing clearance. Additional information can be obtained from the Company website: www.lbti.com Lifeline competes in the money markets for funds to support the development of its product. The cost of funds, for early stage companies like Lifeline, are expensive and the terms have been, and may continue to be, dilutive. Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing, successful development of the Company�s product and regulatory and shareholder approval for anticipated actions.